These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12043492)

  • 1. [Working place codes--a dreary decision].
    Boréus L
    Lakartidningen; 2002 Apr; 99(16):1855. PubMed ID: 12043492
    [No Abstract]   [Full Text] [Related]  

  • 2. [Protest against registration of bar-codes of all prescriptions!].
    Lakartidningen; 1997 Dec; 94(51-52):4878, 4880. PubMed ID: 9454003
    [No Abstract]   [Full Text] [Related]  

  • 3. [Choice of drugs--by whom, for whom and to what costs?].
    Frisk M; Strömstedt A
    Lakartidningen; 2000 Sep; 97(39):4343-6. PubMed ID: 11076479
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug information--national decision needed].
    Ohman U; Nilsson A
    Lakartidningen; 2008 Jul 9-22; 105(28-29):2038. PubMed ID: 18711826
    [No Abstract]   [Full Text] [Related]  

  • 5. [Discount drugs--for the "politically correct" only?].
    Bergholm U
    Lakartidningen; 2002 Apr; 99(16):1855. PubMed ID: 12043493
    [No Abstract]   [Full Text] [Related]  

  • 6. [Introduce prescription codes on sickness certificates and a national registry of sick leave].
    Aurivillius M
    Lakartidningen; 2004 Mar; 101(11):1020-1. PubMed ID: 15055126
    [No Abstract]   [Full Text] [Related]  

  • 7. [Is the registration of drug prescriptions of some benefit?].
    Quensel M
    Lakartidningen; 1998 Aug; 95(34):3510. PubMed ID: 9742841
    [No Abstract]   [Full Text] [Related]  

  • 8. [Only professionals can interpret medical data on prescriptions].
    Brorsson A; Hegle T; Henningsson S; Malmberg BG; Persson M; Staf O; Widäng K
    Lakartidningen; 1997 Jul; 94(30-31):2632. PubMed ID: 9273421
    [No Abstract]   [Full Text] [Related]  

  • 9. [Should the physician not prescribe the best possible drug for the patient?].
    Lidbrink E
    Lakartidningen; 1998 Jun; 95(25):2919-20. PubMed ID: 9674357
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 11. [The prescription registry must be used correctly: quality improvement--not a basis for sanctions].
    Eliasson G
    Lakartidningen; 1996 Mar; 93(13):1197-8. PubMed ID: 8656830
    [No Abstract]   [Full Text] [Related]  

  • 12. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug utilization decisions should be based on cost-benefit data].
    Bengt J; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Apr 18-24; 102(16):1264-5; discussion 1265. PubMed ID: 15921102
    [No Abstract]   [Full Text] [Related]  

  • 14. Canadian prescription drug costs surpass 18 billion dollars.
    Morgan S
    CMAJ; 2005 May; 172(10):1323-4. PubMed ID: 15883408
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost of drugs: a policy conundrum of global proportions.
    Barry DR; Romig B
    N C Med J; 2003; 64(6):287-8. PubMed ID: 14983620
    [No Abstract]   [Full Text] [Related]  

  • 16. [Quality indicators for drug prescribing--the situation in Sweden].
    Wettermark B; Tomson G; Bergman U
    Lakartidningen; 2006 Nov 15-21; 103(46):3607-11. PubMed ID: 17153869
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 18. The new drug war.
    Parloff R
    Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is there a risk of revision in connection with the drug reform?].
    Danielsson S
    Lakartidningen; 2002 May; 99(20):2332. PubMed ID: 12082959
    [No Abstract]   [Full Text] [Related]  

  • 20. Advocating for a Medicare prescription drug benefit.
    Rother J
    Yale J Health Policy Law Ethics; 2003; 3(2):279-90. PubMed ID: 14577144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.